News | July 09, 2010

Lantheus Medical, MDS Nordion to Produce More of Medical Isotope

July 9, 2010 – Lantheus Medical Imaging Inc. announced this week that it has signed a new manufacturing and supply agreement with MDS Nordion to purchase molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m). Mo-99 is used in Lantheus Medical Imaging’s TechneLite generators, which are sold throughout the world, and which produce Tc-99m, a medical isotope widely used in nuclear medicine imaging.

Under terms of the new agreement, Lantheus will begin receiving additional supplies of Mo-99 on a weekly basis once the National Research Universal (NRU) reactor is back online, which is currently anticipated to be at the end of July 2010. The contract is in place until July 31, 2011.

“Our agreement with MDS Nordion is part of Lantheus Medical Imaging’s aggressive supply chain strategy to strengthen our Mo-99 supply by working with major suppliers around the world in helping to meet the medical isotope needs of our customers in North America,” said Don Kiepert, president and chief executive officer, Lantheus Medical Imaging Inc.

“This agreement represents MDS Nordion and Lantheus’ commitment to provide medical isotopes to the global nuclear medicine community,” said Steve West, chief executive officer, MDS Inc. “The Nordion team has been actively preparing for the NRU restart and we have taken the steps necessary to assume our role in the supply chain and resume the processing of isotopes for patients worldwide.”

Over 21 million doses of diagnostic radiopharmaceuticals were injected into patients in the United States during 2009. Of these, 65 percent were for cardiac exams, with the remaining for oncology, neurology and other applications. Tc-99m, which is the decay product of Mo-99, is the most commonly used medical radioisotope in the United States. At 16.7 million doses, Tc-99m accounted for 80 percent of all diagnostic radiopharmaceutical injections.

Tc-99m is used in Lantheus Medical Imaging’s TechneLite generators, which are distributed to radiopharmacies and hospitals as a source of Tc-99m for diagnostic imaging procedures. In diagnostic use, the Tc-99m is attached to a specific molecule and injected into the patient. The diagnostic medicine then travels to the site or organ of interest and a special camera is used to pick up the gamma rays emitted from the radioactive material in the body and to create images for diagnostic evaluation.

Related Content

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma

This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma. The quarter dose image on the left was obtained after the administration of 4 ml of MultiHance. Subsequently, an additional 12 ml of MultiHance was administered and the cumulative full dose image in the center was obtained. The image on the right was rendered following artificial intelligence processing of the 4 ml image using eGad genetic algorithms. This image has the quality of triple dose gadolinium even though only one quarter dose gadolinium was given.

Feature | Contrast Media Injectors | January 30, 2020 | By Matthew Kuhn, M.D., FACR
Gadolinium-based contrast agents (...

Image courtesy of Mallinckrodt

Feature | Contrast Media Injectors | January 30, 2020 | By Melinda Taschetta-Millane
Contrast media injector technology has seen several recent advances, such as cutting costs by reducing contrast waste
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Nuclear imaging of the spine shown on Philips Healthcare BrightView XCT

Image courtesy of Philips Healthcare

News | Nuclear Imaging | January 27, 2020
January 27, 2020 — According to the new market research report "...
Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

News | Nuclear Imaging | December 26, 2019
December 26, 2019 — The Feinstein Institutes for Medical R...
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...
Image by Dr. Manuel González Reyes from Pixabay

Image by Dr. Manuel González Reyes from Pixabay 

News | SPECT Imaging | November 08, 2019
November 8, 2019 — Using ground-breaking technology, researchers at the...